vs
Side-by-side financial comparison of PLEXUS CORP (PLXS) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.3B vs $1.2B, roughly 1.9× PLEXUS CORP). Zoetis runs the higher net margin — 26.6% vs 4.3%, a 22.3% gap on every dollar of revenue. On growth, PLEXUS CORP posted the faster year-over-year revenue change (18.7% vs 2.9%). Over the past eight quarters, PLEXUS CORP's revenue compounded faster (7.2% CAGR vs -2.1%).
Plex Systems, Inc. is an American software company based in Troy, Michigan. The company develops and markets the Plex Manufacturing Cloud, a software as a service (SaaS) or cloud computing ERP for manufacturing.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
PLXS vs ZTS — Head-to-Head
Income Statement — Q2 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $2.3B |
| Net Profit | $49.8M | $601.0M |
| Gross Margin | 10.2% | 71.7% |
| Operating Margin | 5.3% | — |
| Net Margin | 4.3% | 26.6% |
| Revenue YoY | 18.7% | 2.9% |
| Net Profit YoY | 27.5% | -0.2% |
| EPS (diluted) | $1.82 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.1B | $2.3B | ||
| Q4 25 | — | $2.4B | ||
| Q3 25 | — | $2.4B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | — | $2.3B | ||
| Q3 24 | — | $2.4B | ||
| Q2 24 | — | $2.4B |
| Q1 26 | $41.2M | $601.0M | ||
| Q4 25 | — | $603.0M | ||
| Q3 25 | — | $721.0M | ||
| Q2 25 | — | $718.0M | ||
| Q1 25 | — | $631.0M | ||
| Q4 24 | — | $581.0M | ||
| Q3 24 | — | $682.0M | ||
| Q2 24 | — | $624.0M |
| Q1 26 | 9.9% | 71.7% | ||
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% |
| Q1 26 | 5.1% | — | ||
| Q4 25 | — | 31.9% | ||
| Q3 25 | — | 37.0% | ||
| Q2 25 | — | 36.7% | ||
| Q1 25 | — | 36.5% | ||
| Q4 24 | — | 31.6% | ||
| Q3 24 | — | 36.6% | ||
| Q2 24 | — | 33.0% |
| Q1 26 | 3.8% | 26.6% | ||
| Q4 25 | — | 25.3% | ||
| Q3 25 | — | 30.0% | ||
| Q2 25 | — | 29.2% | ||
| Q1 25 | — | 28.4% | ||
| Q4 24 | — | 25.1% | ||
| Q3 24 | — | 28.6% | ||
| Q2 24 | — | 26.4% |
| Q1 26 | $1.51 | $1.42 | ||
| Q4 25 | — | $1.37 | ||
| Q3 25 | — | $1.63 | ||
| Q2 25 | — | $1.61 | ||
| Q1 25 | — | $1.41 | ||
| Q4 24 | — | $1.29 | ||
| Q3 24 | — | $1.50 | ||
| Q2 24 | — | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $303.1M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.5B | — |
| Total Assets | $3.4B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $248.8M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.6B |
| Q1 26 | $1.5B | — | ||
| Q4 25 | — | $3.3B | ||
| Q3 25 | — | $5.4B | ||
| Q2 25 | — | $5.0B | ||
| Q1 25 | — | $4.7B | ||
| Q4 24 | — | $4.8B | ||
| Q3 24 | — | $5.2B | ||
| Q2 24 | — | $5.0B |
| Q1 26 | $3.2B | — | ||
| Q4 25 | — | $15.5B | ||
| Q3 25 | — | $15.2B | ||
| Q2 25 | — | $14.5B | ||
| Q1 25 | — | $14.1B | ||
| Q4 24 | — | $14.2B | ||
| Q3 24 | — | $14.4B | ||
| Q2 24 | — | $14.2B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PLXS
| Asia-Pacific | $652.0M | 56% |
| Americas | $397.0M | 34% |
| Europe, Middle East and Africa | $116.0M | 10% |
ZTS
| Companion Animal | $1.5B | 67% |
| Livestock | $720.0M | 32% |
| Contract Manufacturing & Human Health | $23.0M | 1% |
